Document:

1

                   REORGANIZATION AND STOCK PURCHASE AGREEMENT

      This  REORGANIZATION AND STOCK PURCHASE AGREEMENT dated as of September 1,
2005  (this  "Agreement") is by and between Altadyne, Inc., a Nevada corporation
("ATYD"),  Stem  Cell  Therapy  International,  Corp.,  a  Florida  corporation
("SCTI"),  and  R  Capital  Partners,  Inc.  ("R  Capital").
RECITALS

A.     WHEREAS,  R  Capital  partners  has  introduced  SCTI  to  ATYD, and ATYD
desires  to  acquire  directly  or  indirectly  100%  of  the  equity  of  SCTI;

B:     WHEREAS, the shareholders of SCTI desire to exchange their shares of SCTI
for  equity  in  ATYD;

C:     WHEREAS, the parties hereto intend that the transaction contemplated here
by  shall  be  completed  as  a  tax-free  exchange  of  stock.

NOW,  THEREFORE,  The  respective  Boards  of Directors of ATYD and SCTI deem it
advisable  and  in  the  best interests of their corporations and the respective
shareholders  of  their corporations that ATYD acquire 100% of the securities of
SCTI,  in  accordance  with  the terms and conditions of this Reorganization and
Stock  Purchase  Agreement.

1.     Pre-Closing Actions ofATYD.  Immediately upon execution of this Agreement
       --------------------------
and prior to any Closing as set forth herein, ATYD shall undertake the following
actions:

(a)     The  Board of Directors of ATYD shall unanimously approve and deliver to
Cutler  Law Group ("Escrow") in escrow resolutions with respect to (a) approving
the  Transactions  set forth herein; (c) increasing or directing the size of the
Board  of  Directors  to  be  two  members;  (c)  electing Calvin Cao and Daniel
Sullivan  to  the board of directors of ATYD, and (d) approving a name change of
the  corporation  to  Stem  Cell  Therapy  International,  Inc.

(b)     Shareholders  of  ATYD  shall deliver together with medallion guaranteed
stock  powers shares of ATYD and/or ATYD shall issue and deliver to Escrow for a
total  of  25,000,000  shares  of  ATYD  for  delivery  to shareholders or other
designees  of  SCTI  as  advised  to Escrow prior to closing (the "Escrowed ATYD
Shares").

(c)     ATYD  shall  use its reasonable best efforts to prepare and complete the
documents  necessary  to  be  filed with local, state and federal authorities to
consummate  the  transactions  contemplated  hereby.

(d)     During  a period from the date of this Agreement until September 6, 2005
(the  "Due  Diligence  Period"),  ATYD  shall  make available to SCTI and SCTI's
employees,  attorneys,  accountants,  financial  advisors,  agents  and
representatives  during  normal  business  hours  all information concerning the
operation,  business  and  prospects  of  ATYD as may be reasonably requested by
SCTI.  ATYD  will  cooperate  with  SCTI  for  the purpose of permitting SCTI to
discuss  ATYD's  historical  business,  including  without  limitation providing
access  to  all  employees,  consultants,  assets,  properties, books, accounts,
records,  tax  returns,  contracts  and  other  documents  of  ATYD.

2.     Pre-Closing  Action ofSCTI.  Immediately upon execution of this Agreement
       --------------------------
and prior to the Closing as set forth herein, SCTI shall undertake the following
actions:

(a)     The  Board  of  Directors  of SCTI shall execute and deliver resolutions
unanimously  approving  the  Transactions  set  forth  herein.

(b)     The  shareholders  of  SCTI  shall deliver to Cutler Law Group in escrow
certificates  representing  25,000,000  shares  of  common  stock  of  SCTI (the
"Escrowed  SCTI Shares"), representing 100% of the issued and outstanding equity
of  SCTI,  for  delivery  to  ATYD  at  Closing.

(f)     During  the  Due Diligence Period, SCTI shall make available to ATYD and
ATYD's  employees,  attorneys,  accountants,  financial  advisors,  agents  and
representatives  during  normal  business  hours  all information concerning the
operation,  business  and  prospects  of  SCTI as may be reasonably requested by
ATYD.  SCTI  will  cooperate  with  ATYD  for  the purpose of permitting ATYD to
discuss  SCTI's  business and prospects with customers, creditors, suppliers and
other  persons  having  business  dealings  with  such  party, including without
limitation  providing  access to all employees, consultants, assets, properties,
books,  accounts,  records,  tax returns, contracts and other documents of SCTI,
provided that such access will not materially interfere with the normal business
operations  of  SCTI.

3.     Conditions  to  Closing
       -----------------------

The  parties'  obligation  to  close the proposed Acquisition will be subject to
specified  conditions  precedent  including,  but not limited to, the following:

(a)     the  representations  and  warranties  of ATYD as set forth in Section 6
herein  shall  remain  accurate  as  of the Closing Date and no material adverse
change  in  the  business  of  ATYD  shall  have  occurred;

(b)     the  representations  and  warranties  of SCTI as set forth in Section 7
herein  shall  remain  accurate  as  of the Closing Date and no material adverse
change  in  the  business  of  SCTI  shall  have  occurred;

(c)     all  the  documents  necessary to be filed with local, state and federal
authorities  are  prepared

(d)     ATYD  shall  have  provided the board resolutions and any other approval
required  to  complete  the  board  election  and  the  name  change.

(e)     ATYD  shall  retain its good standing as a publicly traded company under
the Securities Exchange Act, trading on the pink sheets under the symbol "ATYD".

4.     At  the  Closing.
       -----------------

(a)     At  the  Closing,  Cutler  Law  Group shall release from escrow the ATYD
Board  Resolutions  effectuating the election of two new members of the Board of
Directors.  The members of the Board of Directors of ATYD prior to Closing shall
submit  resignations  at  Closing.

(b)     At  the Closing, Cutler Law Group shall release the Escrowed SCTI Shares
to  ATYD.

(c)     At  the  Closing,  the  existing  officers  of  ATYD shall resign and be
replaced  by  those  officers  appointed  by  the  new  Board  of  Directors.

5.     Timing  of Closing.  The Closing shall occur upon the satisfaction of the
       ------------------
conditions  set  forth  in this Agreement and upon instructions from the parties
hereto to the Escrow Agent.  The Closing Date shall occur on or before September
6,  2005,  unless  the  Escrow  Agent  receives  instructions otherwise from the
parties  or  notice  from  a party that the conditions set forth herein have not
occurred.  In  the  event  the Closing does not occur on or before September 30,
2005,  (i)  the  Escrow  Agent shall return the Escrowed ATYD Shares to ATYD and
(ii)  the Escrow Agent shall return the Escrowed SCTI Shares to the shareholders
of  SCTI.

6.     Representations  ofATYD.  ATYD  represents  and  warrants  as  follows:
       ------------------------

(a)     Ownership  of  Shares.  As of the Closing Date, the shareholders of SCTI
will  become  the  owners of the Escrowed ATYD Shares.  The Escrowed ATYD Shares
will  be free from claims, liens or other encumbrances, except as provided under
applicable  federal  and  state  securities  laws;

(b)     Fully  paid and Nonassessable.  The Escrowed ATYD Shares constitute duly
and  validly  issued  shares  of ATYD, and are fully paid and nonassessable, and
ATYD  further represents that it has the power and the authority to execute this
Agreement  and  to  perform  the  obligations  contemplated  hereby;

(c)     Organization  of  ATYD;  Authorization.  ATYD  is  a  corporation  duly
organized,  validly  existing and in good standing under the laws of Nevada with
full  corporate power and authority to execute and deliver this Agreement and to
perform  its  obligations  hereunder. The execution, delivery and performance of
this  Agreement  have  been duly authorized by all necessary corporate action of
ATYD  and  this  Agreement  constitutes  a valid and binding obligation of ATYD;
enforceable  against it in accordance with its terms.  ATYD has no subsidiaries.

(d)     Capitalization.  The  authorized  capital  stock  of  ATYD  consists  of
100,000,000 shares of common stock, par value $0.001 per share, and no shares of
preferred  stock.  As  of  the Closing Date, ATYD will have a total of 8,400,000
shares  of  common stock issued and outstanding (not including the Escrowed ATYD
Shares) and no shares of preferred stock issued and outstanding.  No shares have
otherwise  been  registered  under  state or federal securities laws.  As of the
Closing  Date,  all of the issued and outstanding shares of common stock of ATYD
are validly issued, fully paid and non-assessable and there is not and as of the
Closing  Date,  except for 250,000 cashless exercise warrants to purchase shares
of  ATYD common stock at an exercise price of $1.00 per share held by R Capital,
there  will  not be outstanding any warrants, options or other agreements on the
part  of  ATYD  obligating  ATYD  to  issue  any  additional shares of common or
preferred  stock  or any of its securities of any kind.  ATYD will not issue any
shares  of  capital  stock  from  the date of this Agreement through the Closing
Date.  The  Common  Stock  of ATYD is presently trading on the pink sheets under
the  symbol  "ATYD".

(e)     Ownership  of  ATYD Shares. The delivery of certificates provided herein
for  the Escrowed ATYD Shares will result in the shareholders of SCTI or assigns
immediate  acquisition  of  record and beneficial ownership of the Escrowed ATYD
Shares,  free  and  clear  of  all  encumbrances.

(f)     No  Conflict  as  to  ATYD  and Subsidiaries.  Neither the execution and
delivery  of  this  Agreement  nor  the consummation of the exchange of the ATYD
Shares  will  (a)  violate  any provision of the certificate of incorporation or
by-laws  (or  other  governing  instrument)  of  ATYD  or  (b) violate, or be in
conflict  with, or constitute a default (or an event which, with notice or lapse
of time or both, would constitute a default) under, or result in the termination
of,  or  accelerate  the  performance  required by, or excuse performance by any
Person  of  any  of  its  obligations  under,  or  cause the acceleration of the
maturity  of  any  debt  or obligation pursuant to, or result in the creation or
imposition  of  any  Encumbrance  upon any property or assets of ATYD under, any
material  agreement  or  commitment  to  which  ATYD  is a party or by which its
property  or  assets is bound, or to which any of the property or assets of ATYD
is  subject,  or  (c) violate any statute or law or any judgment, decree, order,
regulation  or  rule  of any court or other Governmental Body applicable to ATYD
except,  in  the  case  of  violations,  conflicts,  defaults,  terminations,
accelerations  or  encumbrances described in clause (b) of this Section for such
matters  which  are not likely to have a material adverse effect on the business
or  financial  condition  of  ATYD.

(g)     Consents and Approvals of Governmental Authorities. No consent, approval
or  authorization  of,  or  declaration,  filing  or  registration  with,  any
Governmental  Body is required to be made or obtained by ATYD in connection with
the  execution,  delivery  and  performance  of  this  Agreement  by ATYD or the
consummation  of  the  sale  of  the  Escrowed  ATYD  Shares.

(h)     Other  Consents.  No consent of any Person is required to be obtained by
ATYD  to  the  execution,  delivery  and  performance  of  this Agreement or the
consummation  of  the  sale  of  the ATYD Shares, including, but not limited to,
consents  from  parties to leases or other agreements or commitments, except for
any  consent  which the failure to obtain would not be likely to have a material
adverse  effect  on  the  business  and  financial  condition  of  ATYD.

(i)     Litigation.  There  is  no  action,  suit,  inquiry,  proceeding  or
investigation  by or before any Court or Governmental body pending or threatened
in  writing against or involving ATYD which is likely to have a material adverse
effect  on  the  business  or financial condition of ATYD, or which questions or
challenges the validity of this Agreement.  ATYD is not subject to any judgment,
order or decree that is likely to have a material adverse effect on the business
or  financial  condition  of  ATYD.

(j)     Absence  of  Certain  Changes.  ATYD  has  not:

1.     suffered  the  damage  or  destruction of any of its properties or assets
(whether  or  not  covered  by  insurance)  which  is  materially adverse to the
business  or financial condition of  ATYD, or made any disposition of any of its
material  properties  or  assets  other than in the ordinary course of business;

2.     made  any  change  or  amendment  in  its certificate of incorporation or
by-laws,  or  other  governing  instruments;

3.     other than the ATYD Escrowed Shares, issued or sold any Equity Securities
or  other  securities,  acquired,  directly  or  indirectly,  by  redemption  or
otherwise,  any  such  Equity  Securities,  reclassified,  split-up or otherwise
changed  any  such  Equity  Security,  or  granted  or entered into any options,
warrants,  calls  or  commitments  of  any  kind  with  respect  thereto;

4.     organized  any  new  Subsidiary  or acquired any Equity Securities of any
Person  or  any  equity  or  ownership  interest  in  any  business;

5.     borrowed  any funds or incurred, or assumed or become subject to, whether
directly  or  by way of guarantee or otherwise, any obligation or liability with
respect  to  any  such  indebtedness  for  borrowed  money;

6.     paid, discharged or satisfied any material claim, liability or obligation
(absolute,  accrued, contingent or otherwise), other than in the ordinary course
of  business;

7.     prepaid  any  material  obligation having a maturity of more than 90 days
from  the  date  such  obligation  was  issued  or  incurred;

8.     cancelled  any  material  debts  or waived any material claims or rights,
except  in  the  ordinary  course  of  business;

9.     disposed  of  or permitted to lapse any rights to the use of any material
patent or registered trademark or copyright or other intellectual property owned
or  used  by  it;

10.     granted  any  general  increase  in  the  compensation  of  officers  or
employees  (including  any such increase pursuant to any employee benefit plan);

11.     purchased  or  entered  into  any contract or commitment to purchase any
material  quantity  of  raw  materials  or supplies, or sold or entered into any
contract  or  commitment  to  sell  any material quantity of property or assets;

12.     made  any  capital  expenditures  or  additions  to  property,  plant or
equipment  or  acquired  any  other  property  or  assets;

13.     written  off  or  been  required  to  write  off  any  notes or accounts
receivable;

14.     written  down  or  been  required  to  write  down  any  inventory;

15.     entered  into  any collective bargaining or union contract or agreement;
or

16.     incurred  any  liability.

(k)     Contracts  and  Commitments.  ATYD  is  not  a  party  to  any:

1.     Contract  or  agreement  involving  any  liability  on  the part of ATYD.

2.     Lease  of  personal  property;

3.     Employee  bonus,  stock  option  or  stock  purchase,  performance  unit,
profit-sharing,  pension,  savings,  retirement,  health,  deferred or incentive
compensation,  insurance  or other material employee benefit plan (as defined in
Section  2(3) of ERISA) or program for any of the employees, former employees or
retired  employees  of  ATYD;

4.     Commitment,  contract  or  agreement  that  is  currently expected by the
management of ATYD to result in any material loss upon completion or performance
thereof;

5.     Contract,  agreement  or  commitment  with  any officer, employee, agent,
consultant,  advisor,  salesman,  sales  representative,  value  added reseller,
distributor  or  dealer;  or

6.     Employment  agreement  or  other  similar  agreement.

(l)     Compliance  with  Law.  The  operations  of  ATYD have been conducted in
accordance  with  all applicable laws and regulations of all Governmental Bodies
having  jurisdiction  over  them,  except  for  violations thereof which are not
likely  to have a material adverse effect on the business or financial condition
of  ATYD. ATYD has not received any notification of any asserted present or past
failure  by it to comply with any such applicable laws or regulations.  ATYD has
all material licenses, permits, orders or approvals from the Governmental Bodies
required  for  the  conduct of its business, and is not in material violation of
any  such  licenses,  permits, orders and approvals. All such licenses, permits,
orders  and  approvals  are  in  full  force  and  effect,  and no suspension or
cancellation  of  any  thereof  has  been  threatened.

(m)     Tax  Matters.

1.     ATYD (1) has filed or shall file prior to Closing all nonconsolidated and
noncombined  Tax  Returns  and  all  consolidated  or  combined Tax Returns that
include only ATYD and not SCTI or its other Affiliates (for the purposes of this
Section,  such  tax  Returns shall be considered nonconsolidated and noncombined
Tax Returns) required to be filed through the date hereof and will have paid any
Tax due through the date hereof with respect to the time periods covered by such
nonconsolidated  and noncombined Tax Returns and shall timely pay any such Taxes
required to be paid by it after the date hereof with respect to such Tax Returns
and  (2)  shall prepare and timely file all such nonconsolidated and noncombined
Tax  Returns  required to be filed after the date hereof and through the Closing
Date  and  pay  all  Taxes required to be paid by it with respect to the periods
covered  by  such Tax Returns; (B) all such Tax Returns filed pursuant to clause
(A) after the date hereof shall, in each case, be prepared and filed in a manner
consistent  in all material respects (including elections and accounting methods
and  conventions)  with  such  Tax  Return  most  recently filed in the relevant
jurisdiction  prior  to  the date hereof, except as otherwise required by law or
regulation.  Any  such  Tax  Return filed or required to be filed after the date
hereof shall not reflect any new elections or the adoption of any new accounting
methods  or  conventions  or  other  similar  items,  except  to the extent such
particular  reflection  or  adoption  is  required  to  comply  with  any law or
regulation.

2.     ATYD  represents  that prior to Closing, all consolidated or combined Tax
Returns  (except those described in subparagraph (1) above) required to be filed
by  any person through the date hereof that are required or permitted to include
the income, or reflect the Activities, operations and Transactions, of  ATYD for
any  taxable  period  shall  have been timely filed, and the income, activities,
operations  and  Transactions  of  ATYD  shall  have  been properly included and
reflected  thereon.  ATYD  shall  prepare  and file, or cause to be prepared and
filed,  all  such  consolidated  or  combined  Tax  Returns that are required or
permitted  to  include  the  income,  or  reflect the activities, operations and
Transactions,  of  ATYD, with respect to any taxable year or the portion thereof
ending  on  or  prior to the Closing Date, including, without limitation, ATYD's
consolidated federal income tax return for such taxable years. Prior to Closing,
ATYD  will  timely file a consolidated federal income tax return for the taxable
year  ended  December  31,  2004  and  such return shall include and reflect the
income,  activities,  operations and Transactions of ATYD for the taxable period
then  ended,  and  hereby  expressly covenants and agrees to file a consolidated
federal  income  tax  return,  and  to  include  and reflect thereon the income,
activities,  operations and Transactions of  ATYD for the taxable period through
the Closing Date.  All Tax Returns filed pursuant to this subparagraph (2) after
the  date  hereof  shall,  in  each  case,  to  the extent that such Tax Returns
specifically  relate  to  ATYD  and do not generally relate to matters affecting
other  members  of  ATYD's consolidated group, be prepared and filed in a manner
consistent  in all material respects (including elections and accounting methods
and  conventions)  with  the  Tax  Return  most  recently  filed in the relevant
jurisdictions  prior  to the date hereof, except as otherwise required by law or
regulation.  ATYD  has  paid  or will pay all Taxes that may now or hereafter be
due with respect to the taxable periods covered by such consolidated or combined
Tax  Returns.

3.     There  is no (nor has there been any request for an) agreement, waiver or
consent providing for an extension of time with respect to the assessment of any
Taxes attributable to ATYD, or its assets or operations and no power of attorney
granted  by  ATYD  with  respect  to  any  Tax  matter  is  currently  in force.

4.     There  is  no  action,  suit,  proceeding,  investigation,  audit, claim,
demand,  deficiency  or additional assessment in progress, pending or threatened
against  or  with  respect  to  any  Tax  attributable  to ATYD or its assets or
operations.

5.     All  amounts  required to be withheld as of the Closing Date for Taxes or
otherwise  have  been  withheld  and  paid when due to the appropriate agency or
authority.

(n)     Borrowing  and  Guarantees.  ATYD (a) does not have any indebtedness for
borrowed  money,  (b) are not lending or committed to lend any money (except for
advances  to  employees  in  the  ordinary  course of business), and (c) are not
guarantors  or  sureties  with  respect  to  the  obligations  of  any  Person.

7.     Representations  ofSCTI.  SCTI  for their respective rights and interests
       -----------------------
represent  and  warrant  as  follows:
(a)     Organization;  Authorization.  SCTI  is  a  corporation  duly organized,
validly  existing  and  in  good  standing  under  the  laws of Nevada with full
corporate  power  and  authority  to  execute  and deliver this Agreement and to
perform  its  obligations  hereunder. The execution, delivery and performance of
this  Agreement  have  been duly authorized by all necessary corporate action of
SCTI  and this Agreement constitutes a valid and binding obligation; enforceable
against  in  accordance  with  its  terms.  SCTI  has  no  subsidiaries.

(b)     Capitalization.  The  authorized  capital  stock  of  SCTI  consists  of
____________  shares  of common stock, par value $_____ per share, and no shares
of preferred stock, par value $____ per share  As of the date of this Agreement,
SCTI  has 25,000,000 shares of common stock issued and outstanding and no shares
of  preferred  stock  issued  and  outstanding.  No  shares  have otherwise been
registered  under state or federal securities laws.  As of the Closing Date, all
of the issued and outstanding shares of common stock of SCTI are validly issued,
fully  paid and non-assessable and there is not and as of the Closing Date there
will not be outstanding any warrants, options or other agreements on the part of
SCTI  obligating  any  of  SCTI  to  issue  any  additional  shares of common or
preferred  stock  or  any  of  its securities of any kind.  Except for 5,000,000
shares  to  be  issued to Institute of Cell Therapy ("ICT") in accordance with a
Licensing Agreement dated as of September 1, 2005 between SCTI and ICT (the "ICT
Agreement"),  SCTI  will  not issue any shares of capital stock from the date of
this  Agreement  through  the  Closing  Date.

(c)     No  Conflict  as  to  SCTI  and Subsidiaries.  Neither the execution and
delivery of this Agreement nor the consummation of the transactions contemplated
herein  will  (a)  violate  any  provision  of  the articles of incorporation or
organization  of  SCTI  or  any  of  its  Subsidiaries  or (b) violate, or be in
conflict  with, or constitute a default (or an event which, with notice or lapse
of time or both, would constitute a default) under, or result in the termination
of,  or  accelerate  the  performance  required by, or excuse performance by any
Person  of  any  of  its  obligations  under,  or  cause the acceleration of the
maturity  of  any  debt  or obligation pursuant to, or result in the creation or
imposition  of any Encumbrance upon any property or assets of any of SCTI or any
of  its Subsidiaries under, any material agreement or commitment to which any of
SCTI,  any  of  its  Subsidiaries is a party or by which any of their respective
property or assets is bound, or to which any of the property or assets of any of
SCTI or any of its Subsidiaries is subject, or (c) violate any statute or law or
any  judgment,  decree,  order,  regulation  or  rule  of  any  court  or  other
Governmental  Body  applicable to SCTI or any of its Subsidiaries except, in the
case  of  violations,  conflicts,  defaults,  terminations,  accelerations  or
Encumbrances  described in clause (b) of this Section for such matters which are
not  likely  to  have  a  material  adverse  effect on the business or financial
condition  of  SCTI  and  its  subsidiaries,  taken  as  a  whole.

(d)     Consents and Approvals of Governmental Authorities. No consent, approval
or  authorization  of,  or  declaration,  filing  or  registration  with,  any
Governmental Body is required to be made or obtained by SCTI or any of either of
its  Subsidiaries  in connection with the execution, delivery and performance of
this  Agreement  by  SCTI  or  the consummation of the transactions contemplated
herein.

(e)     Other  Consents.  No consent of any Person is required to be obtained by
SCTI  to  the  execution,  delivery  and  performance  of  this Agreement or the
consummation of the transactions contemplated herein, including, but not limited
to,  consents  from parties to leases or other agreements or commitments, except
for  any  consent  which  the  failure  to  obtain would not be likely to have a
material  adverse  effect  on  the  business  and  financial  condition of SCTI.

(f)     Buildings,  Plants  and Equipment. The buildings, plants, structures and
material  items of equipment and other personal property owned or leased by SCTI
or  its  Subsidiaries are, in all respects material to the business or financial
condition  of  SCTI  and  its  Subsidiaries, taken as a whole, in good operating
condition  and  repair (ordinary wear and tear excepted) and are adequate in all
such  respects  for  the  purposes  for which they are being used.  SCTI has not
received  notification  that  it  is  in  violation  of any applicable building,
zoning,  anti-pollution, health, safety or other law, ordinance or regulation in
respect  of  its  buildings,  plants  or  structures  or their operations, which
violation  is  likely  to  have  a  material  adverse  effect on the business or
financial  condition  of  SCTI  and  its Subsidiaries, taken as a whole or which
would  require a payment by SCTI or any of its subsidiaries in excess of  $2,000
in  the  aggregate,  and  which  has  not  been  cured.

(g)     No  Condemnation  or Expropriation. Neither the whole nor any portion of
the  property  or leaseholds owned or held by SCTI or any of its Subsidiaries is
subject  to  any  governmental decree or order to be sold or is being condemned,
expropriated or otherwise taken by any Governmental Body or other Person with or
without  payment  of  compensation  therefore,  which action is likely to have a
material  adverse  effect on the business or financial condition of SCTI and its
Subsidiaries,  taken  as  a  whole.

(h)     Litigation.  There  is  no  action,  suit,  inquiry,  proceeding  or
investigation  by or before any court or Governmental Body pending or threatened
in  writing against or involving SCTI or any of its Subsidiaries which is likely
to have a material adverse effect on the business or financial condition of SCTI
and any of its Subsidiaries, taken as whole, or which would require a payment by
SCTI or its subsidiaries in excess of $2,000 in the aggregate or which questions
or  challenges  the  validity  of  this  Agreement.  Neither SCTI nor any or its
Subsidiaries  is subject to any judgment, order or decree that is likely to have
a  material adverse effect on the business or financial condition of SCTI or any
of  its Subsidiaries, taken as a whole, or which would require a payment by SCTI
or  its  Subsidiaries  in  excess  of  $2,000  in  the  aggregate.

(i)     Absence  of  Certain  Changes. Neither  SCTI nor any of its Subsidiaries
has:

1.     suffered  the  damage  or  destruction of any of its properties or assets
(whether  or  not  covered  by  insurance)  which  is  materially adverse to the
business or financial condition of  SCTI and its Subsidiaries, taken as a whole,
or  made  any disposition of any of its material properties or assets other than
in  the  ordinary  course  of  business;

2.     made  any  change  or  amendment  in  its certificate of incorporation or
by-laws,  or  other  governing  instruments;

3.     paid, discharged or satisfied any material claim, liability or obligation
(absolute,  accrued, contingent or otherwise), other than in the ordinary course
of  business;

4.     prepaid  any  material  obligation having a maturity of more than 90 days
from  the  date  such  obligation  was  issued  or  incurred;

5.     cancelled  any  material  debts  or waived any material claims or rights,
except  in  the  ordinary  course  of  business;

6.     disposed  of  or permitted to lapse any rights to the use of any material
patent or registered trademark or copyright or other intellectual property owned
or  used  by  it;

7.     granted any general increase in the compensation of officers or employees
(including  any  such  increase  pursuant  to  any  employee  benefit  plan);

8.     purchased  or  entered  into  any  contract or commitment to purchase any
material  quantity  of  raw  materials  or supplies, or sold or entered into any
contract  or  commitment  to  sell  any material quantity of property or assets,
except  (i)  normal  contracts  or  commitments  for the purchase of, and normal
purchases  of,  raw materials or supplies, made in the ordinary course business,
(ii)  normal  contracts  or  commitments  for  the sale of, and normal sales of,
inventory  in  the  ordinary  course  of  business,  and  (iii) other contracts,
commitments,  purchases  or  sales  in  the  ordinary  course  of  business;

9.     written  off  or  been  required  to  write  off  any  notes  or accounts
receivable  in  an  aggregate  amount  in  excess  of  $2,000;

10.     written  down  or  been  required  to  write  down  any  inventory in an
aggregate  amount  in  excess  of  $  2,000;

11.     entered  into  any collective bargaining or union contract or agreement;
or

12.     other  than  the  ordinary  course  of  business, incurred any liability
required  by  generally  accepted  accounting  principles  to  be reflected on a
balance  sheet  and  material to the business or financial condition of SCTI and
their  subsidiaries  taken  as  a  whole.

(j)     Labor  Relations. Neither SCTI nor any of its Subsidiaries is a party to
any  collective  bargaining agreement. Except for any matter which is not likely
to have a material adverse effect on the business or financial condition of SCTI
and  its  Subsidiaries,  taken  as  a whole, (a) SCTI and its Subsidiaries is in
compliance  with  all  applicable  laws  respecting  employment  and  employment
practices,  terms  and  conditions of employment and wages and hours, and is not
engaged  in  any  unfair  labor  practice, (b) there is no unfair labor practice
complaint  against  SCTI  or any of its Subsidiaries pending before the National
Labor  Relations  Board,  (c)  there  is  no  labor strike, dispute, slowdown or
stoppage actually pending or threatened against SCTI or any of its Subsidiaries,
(d) no representation question exists respecting the employees of SCTI or any of
its  Subsidiaries,  (e) neither SCTI nor any of its Subsidiaries has experienced
any  strike,  work  stoppage  or  other  labor difficulty, and (f) no collective
bargaining agreement relating to employees of SCTI or any of its Subsidiaries is
currently  being  negotiated.

(k)     Compliance  with  Law.  The operations of SCTI and its Subsidiaries have
been  conducted  in  accordance  with all applicable laws and regulations of all
Governmental Bodies having jurisdiction over them, except for violations thereof
which  are  not  likely  to  have  a  material adverse effect on the business or
financial  condition  of  SCTI  and its Subsidiaries, taken as a whole, or which
would  not require a payment by SCTI or its Subsidiaries in excess of  $2,000 in
the  aggregate,  or  which  have  been  cured.  Neither  SCTI  nor  any  of  its
Subsidiaries  has  received  any  notification  of  any asserted present or past
failure  by it to comply with any such applicable laws or regulations.  SCTI and
its  Subsidiaries  have all material licenses, permits, orders or approvals from
the  Governmental  Bodies  required for the conduct of their businesses, and are
not  in  material violation of any such licenses, permits, orders and approvals.
All  such  licenses, permits, orders and approvals are in full force and effect,
and  no  suspension  or  cancellation  of  any  thereof  has  been  threatened.

(l)     Tax  Matters.

1.     Each  of  SCTI  and its Subsidiaries (1) has filed or shall file prior to
Closing  all nonconsolidated and noncombined Tax Returns and all consolidated or
combined Tax Returns that include only SCTI and not ATYD or its other Affiliates
(for  the  purposes  of  this  Section,  such  tax  Returns  shall be considered
nonconsolidated  and  noncombined  Tax Returns) required to be filed through the
date  hereof and will have paid any Tax due through the date hereof with respect
to  the time periods covered by such nonconsolidated and noncombined Tax Returns
and  shall  timely  pay  any such Taxes required to be paid by it after the date
hereof  with  respect  to such Tax Returns and (2) shall prepare and timely file
all  such nonconsolidated and noncombined Tax Returns required to be filed after
the  date  hereof  and through the Closing Date and pay all Taxes required to be
paid by it with respect to the periods covered by such Tax Returns; (B) all such
Tax  Returns  filed  pursuant to clause (A) after the date hereof shall, in each
case,  be  prepared  and  filed  in a manner consistent in all material respects
(including  elections  and  accounting  methods  and  conventions) with such Tax
Return  most  recently  filed  in  the  relevant  jurisdiction prior to the date
hereof,  except as otherwise required by law or regulation.  Any such Tax Return
filed  or  required  to be filed after the date hereof shall not reflect any new
elections  or the adoption of any new accounting methods or conventions or other
similar  items,  except  to the extent such particular reflection or adoption is
required  to  comply  with  any  law  or  regulation.

2.     Each  of  SCTI and its Subsidiaries represents that prior to Closing, all
consolidated or combined Tax Returns (except those described in subparagraph (1)
above)  required  to  be  filed  by  any person through the date hereof that are
required  or  permitted  to  include  the  income,  or  reflect  the Activities,
operations and Transactions, of SCTI and its Subsidiaries for any taxable period
shall  have  been  timely  filed,  and  the  income,  activities, operations and
Transactions  of SCTI and its Subsidiaries shall have been properly included and
reflected  thereon.  SCTI  and its Subsidiaries shall prepare and file, or cause
to be prepared and filed, all such consolidated or combined Tax Returns that are
required  or  permitted  to  include  the  income,  or  reflect  the activities,
operations  and  transactions, of SCTI and its Subsidiaries, with respect to any
taxable  year  or  the  portion  thereof ending on or prior to the Closing Date,
including,  without  limitation,  SCTI'  and  Subsidiaries' consolidated federal
income  tax  return  for  such  taxable  years.  Prior  to Closing, SCTI and its
Subsidiaries  will  timely file a consolidated federal income tax return for the
taxable  year  ended December 31, 2004 and such return shall include and reflect
the income, activities, operations and transactions of SCTI and its Subsidiaries
for  the taxable period then ended, and hereby expressly covenants and agrees to
file  a  consolidated  federal  income  tax  return,  and to include and reflect
thereon  the  income,  activities,  operations  and Transactions of SCTI and its
Subsidiaries  for  the taxable period through the Closing Date.  All Tax Returns
filed  pursuant  to  this  subparagraph (2) after the date hereof shall, in each
case,  to  the  extent that such Tax Returns specifically relate to SCTI and its
Subsidiaries,  be  prepared  and  filed  in  a manner consistent in all material
respects  (including  elections and accounting methods and conventions) with the
Tax  Return  most recently filed in the relevant jurisdictions prior to the date
hereof, except as otherwise required by law or regulation.  Each of SCTI and its
Subsidiaries  has  paid  or  will pay all Taxes that may now or hereafter be due
with respect to the taxable periods covered by such consolidated or combined Tax
Returns.

3.     Neither  SCTI  nor its Subsidiaries have agreed, or are required, to make
any  adjustment  (x)  under  Section 481(a) of the Code by reason of a change in
accounting  method  or  otherwise  or  (y)  pursuant to any provision of the Tax
Reform  Act  of 1986, the Revenue Act of 1987 or the Technical and Miscellaneous
Revenue  Act  of  1988.

4.     There  is no (nor has there been any request for an) agreement, waiver or
consent providing for an extension of time with respect to the assessment of any
Taxes  attributable  to  SCTI or its Subsidiaries, or their assets or operations
and no power of attorney granted by SCTI or its Subsidiaries with respect to any
Tax  matter  is  currently  in  force.

5.     There  is  no  action,  suit,  proceeding,  investigation,  audit, claim,
demand,  deficiency  or additional assessment in progress, pending or threatened
against  or  with  respect  to any Tax attributable to SCTI, its Subsidiaries or
their  assets  or  operations.

6.     All  amounts  required to be withheld as of the Closing Date for Taxes or
otherwise  have  been  withheld  and  paid when due to the appropriate agency or
authority.

7.     There shall be delivered or made available to ATYD at or prior to Closing
true  and  complete  copies  of  all  income  Tax  Returns  (or  with respect to
consolidated or combined returns, the portion thereof) and any other Tax Returns
requested  by ATYD as may be relevant to SCTI, its Subsidiaries, or their assets
or operations for any and all periods ending after December 31, 1998, or for any
Tax years which are subject to audit or investigation by any taxing authority or
entity.

(m)     Environmental  Matters.

1.     At  all  times  prior  to the date hereof, SCTI and its Subsidiaries have
complied  in  all  material respects with applicable environmental laws, orders,
regulations,  rules  and  ordinances  relating to the Properties (as hereinafter
defined),  the  violation  of  which would have a material adverse effect on the
business or financial condition of  SCTI and its Subsidiaries, taken as a whole,
or  which  would  require  a  payment  by  SCTI or its Subsidiaries in excess of
$2,000  in  the  aggregate,  and  which  have  been  duly  adopted,  imposed  or
promulgated  by  any  legislative, executive, administrative or judicial body or
officer  of  any  Governmental  Body.

2.     The  environmental licenses, permits and authorizations that are material
to  the  operations  of SCTI and its Subsidiaries, taken as a whole, are in full
force  and  effect.

8.     Stock  Market  Application.
       --------------------------

     ATYD  is  a  Nevada  public  corporation  that currently trades on the Pink
Sheets.  Upon  completion  of  the Closing, R Capital agrees to assist ATYD with
(i) obtain a new CUSIP number; (ii) obtain a new trading symbol, (iii) undertake
any  other  matters required to effectuate the transactions contemplated by this
Agreement,  (iv) assist with the preparation and filing of an initial filing and
SEC  review  of  a  Form 10-SB; and (v) upon approval of such 10-SB, assist SCTI
with  filing  an application for trading on the over-the-counter bulletin or, if
SCTI  meets  the other qualifications, the American Stock Exchange or the Nasdaq
Small  Cap  Market,  including  without  limitation  responding  to  any and all
comments  or  other information requests received by any such market.  SCTI will
be  responsible  for  any  and  all costs associated with such filing (excluding
legal  costs)  including  applicable  audit  costs.

9.Notices.
  -------

     Any  notice which any of the parties hereto may desire to serve upon any of
the other parties hereto shall be in writing and shall be conclusively deemed to
have  been  received  by  the  party at its address, if mailed, postage prepaid,
United  States  mail,  registered,  return  receipt  requested, to the following
addresses:

If  to  ATYD                  c/o  Cutler  Law  Group
                              3206  West  Wimbledon  Drive
                              Augusta,  GA  30909
                              Facsimile  No.:  (706)  243-4206
                              Attention:  M.  Richard  Cutler

If  to  SCTI:                 Stem  Cell  Therapy  International,  Inc.
                              2203  N.  Lois  Avenue,  9th  Floor
                              Tampa,  FL  33607
                              Facsimile  No.:  (813)  830-6112
                              Attn:  Calvin  Cao,  President

If  to  R  Capital:           c/o  Cutler  Law  Group
                              3206  West  Wimbledon  Drive
                              Augusta,  GA  30909
                              Facsimile  No.:  (706)  243-4206
                              Attention:  M.  Richard  Cutler

<PAGE>
10.     Successors.
        ----------

     This Agreement shall be binding upon and inure to the benefit of the heirs,
personal  representatives  and  successors  and  assigns  of  the  parties.

11.     Choice  of  Law.
        ---------------

     This  Agreement shall be construed and enforced in accordance with the laws
of  the  State of New York, and the parties submit to the exclusive jurisdiction
of  the  courts  of  New  York  in  respect  of  all disputes arising hereunder.

12.     Counterparts.
        ------------

     This  Agreement  may  be  signed  in one or more counterparts, all of which
taken  together  shall  constitute  an  entire  agreement.

13.     Confidential  Information.
        -------------------------

     Each  of  ATYD,  SCTI and R Capital hereby acknowledges and agrees that all
information  disclosed  to  each  other whether written or oral, relating to the
other's business activities, its customer names, addresses, all operating plans,
information  relating  to  its  existing services, new or envisioned products or
services  and  the  development  thereof,  scientific, engineering, or technical
information  relating  to  the others business, marketing or product promotional
material,  including brochures, product literature, plan sheets, and any and all
reports  generated  to  customers, with regard to customers, unpublished list of
names,  and  all  information  relating  to  order processing, pricing, cost and
quotations,  and  any  and  all  information  relating  to  relationships  with
customers, is considered confidential information, and is proprietary to, and is
considered the invaluable trade secret of such party (collectively "Confidential
Information").  Any  disclosure  of  any  Confidential  Information by any party
hereto,  its  employees,  or representatives shall cause immediate, substantial,
and  irreparable  harm  and  loss to the other.  Each party understands that the
other desires to keep such Confidential Information in the strictest confidence,
and  that  such  party's  agreement  to  do  so is a continuing condition of the
receipt  and possession of Confidential Information, and a material provision of
this  agreement,  and  a  condition  that  shall survive the termination of this
Agreement.  Consequently,  each party shall use Confidential Information for the
sole  purpose  of  performing  its  obligations  as  provided  herein.

14.     Public  Announcement.
        --------------------

     The  parties  shall  make no public announcement concerning this agreement,
their  discussions or any other letters, memos or agreements between the parties
relating  to  this  agreement until such time as they agree to the contents of a
mutually  satisfactory press release which they intend to release on the date of
execution  of  this Agreement.  Either of the parties, but only after reasonable
consultation  with  the  other, may make disclosure if required under applicable
law.

15.     Entire  Agreement.
        -----------------

     This  Agreement  sets  forth  the entire agreement and understanding of the
Parties  hereto  with  respect  to  the  transactions  contemplated  hereby, and
supersedes  all prior agreements, arrangements and understandings related to the
subject  matter  hereof.  No  understanding,  promise,  inducement, statement of
intention,  representation,  warranty,  covenant  or condition, written or oral,
express  or implied, whether by statute or otherwise, has been made by any Party
hereto  which  is  not  embodied  in  this  Agreement or the written statements,
certificates, or other documents delivered pursuant hereto or in connection with
the  transactions  contemplated hereby, and no party hereto shall be bound by or
liable  for  any  alleged  understanding,  promise,  inducement,  statement,
representation,  warranty,  covenant  or  condition  not  so  set  forth.

16.     Costs  and  Expenses.
        --------------------

     Except as otherwise specifically set forth herein, each party will bear its
own  attorneys,  brokers,  investment  bankers, agents, and finders employed by,
such  party.  The  parties  will indemnify each other against any claims, costs,
losses, expenses or liabilities arising from any claim for commissions, finder's
fees  or  other  compensation  in  connection with the transactions contemplated
herein which may be asserted by any person based on any agreement or arrangement
for  payment  by  the  other  party.

17.     Attorney's  Fees.
        -----------------

     Should  any  action  be  commenced  between  the  parties to this Agreement
concerning  the  matters  set forth in this Agreement or the right and duties of
either  in  relation  thereto,  the  prevailing  party  in  such Action shall be
entitled,  in  addition  to such other relief as may be granted, to a reasonable
sum  as  and  for  its  Attorney's  Fees  and  Costs.

18.     Finders.
        --------

     ATYD  represents  and  warrants  that there are no finders or other parties
which  have  represented  ATYD  in connection with this transaction other than R
Capital which have not received appropriate compensation.  In the event any such
finders  make  a  claim  for  any  fee,  share issuance of other compensation in
connection  with  the  transactions  contemplated hereby, they shall be the sole
responsibility  of ATYD.  SCTI represents and warrants that there are no finders
or  other  parties  which  have  represented  SCTI  in  connection  with  this
transaction.  In  the  event  any  such  finders make a claim for any fee, share
issuance  of other compensation in connection with the transactions contemplated
hereby,  they  shall  be  the  sole  responsibility  of  SCTI.

<PAGE>
IN  WITNESS  WHEREOF,  the parties hereto have executed this Agreement as of the
date  first  above  written.

For  and  on  behalf  of:          Altadyne,  Inc.
                    a  Nevada  corporation

                    By:__________________________
                    M. Richard Cutler
                    President

For and on behalf of:          Stem Cell Therapy International, Corp.
                    a Nevada corporation

                    By:__________________________
                    Calvin Cao
                    President

For and on behalf of:          R Capital Partners, Inc.
                    a  Nevada  corporation

                               [GRAPHIC OMITED]

                    By:__________________________
                    M. Richard Cutler
                    PresidentLICENSING AGREEMENT
This Licensing Agreement ("Agreement") is made effective as of September 1, 2005
by  and  between  Institute  of  Cell  Therapy,  a company duly incorporated and
organized  under  the  laws  of  Kiev, Ukraine ("ICT" or "Licensor"), having its
principal  office  at  4A  Sklyrenko  Street, Kiev, Ukraine 04073, and Stem Cell
Therapy  International  Corp., a corporation duly incorporated under the laws of
Nevada,  with  its  principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida  33607  ("SCTI"  or  "Licensee").
                                    RECITALS
     WHEREAS,  Licensor  is  the  owner  of:  (1) a unique process for producing
biological  solution  of human stem cells (the "Process"); and (2) 26 Patents in
the  name  of  Licensor, the abstract for which in fully set forth in Schedule A
hereto  (the  "Patents");  and (3) products consisting of biological solution of
human  stem  cells  (the  "Products");  and
     WHEREAS,  Licensor  is  in the business of producing biological solution of
human stem cells and engages in continuing research regarding the production and
utilization  of  stem  cells  ;  and
     WHEREAS,  Licensor's business is operated in connection with the use of the
Intellectual  Property  and  in  connection  with  the  Relationships;  and
     WHEREAS,  Licensee has the expertise and experience to utilize the Patents,
the  Products  and  the Process of Licensor in establishing clinics , marketing,
treating  and  administeringstem  cell products to customers, as well as certain
limited  sales to universities, for research or to private labs with appropriate
supervision  by  Licensee  and/or  Licensor;  and
     WHEREAS,  Licensee  has established financial relationships for the purpose
of  taking  the  Company  to  the  public  securities  markets and financing the
proposed  business  sufficient  to adequately promote and undertake its proposed
business  with  respect  to  the  stem  cell  products;  and
     WHEREAS,  Licensee  desires  to  utilize  the  Process, the Patents and the
Products  for  the  purpose  of  establishing  the  proposed  stem cell business
throughout  the  Territory  (the  "Licensee  Business");  and

<PAGE>

     WHEREAS, Licensor has agreed to grant Licensee the exclusive license to the
Patents,  the  Process  and the Products in the Territory in accordance with the
terms  of  this  License  Agreement;  and
     WHEREAS,  Licensor  wishes  to  sell  and  Licensee  wishes to purchase the
Products  consisting  of  biological  solution of human stem cells at the prices
hereinafter  set  forth.
                                   DEFINITIONS
     Unless the context requires otherwise, whenever used in this Agreement the
following terms and expressions shall have the following meaning:
     "AGREEMENT" means this agreement including the Exhibits, Addendums and
Schedules, as they may be amended from time to time.
     "ALLO-TRANSPLANTS"  means  biological  solution of human stem cells used in
transplantation  therapy.
"BUSINESS  DAY"  means  any  day except a Saturday, Sunday or other day on which
commercial banks in the city of New York or in The Ukraine are authorized by law
to  close.
"BUSINESS  METHODS"  means business methods developed, licensed to, and/or owned
or developed by Licensor or Licensee relating to the Patents, the Process or the
Products  .
"CONFIDENTIAL INFORMATION" includes all information, whether written or oral, in
whatever  form  disclosed,  concerning any technologies, products, developments,
business  methods,  business plans, marketing, investment, management, financial
and other business affairs in connection with all matters relating to or arising
out  of  this  Agreement.
"CUSTOMERS" means any natural person(s) or legal entities primarily solicited by
Licensee  under  this  Agreement  in  the  Territory.
"DOING BUSINESS" means transplantation within a given country of a minimum of 60
Transplants  in  any  given  consecutive  twelve  month  period,  whether  such
transplantation  is  done  by  Licensor  alone or by Licensor as part of a joint
venture.
"INTELLECTUAL  PROPERTY"  means  the  Patents,  Processes  and  Confidential
Information
"LIQUIDITY $20,000,000 EVENT" means the cumulative release from the

<PAGE>

Lockup  Agreement  to  Licensor  of  shares  of  common  stock  which are freely
tradeable  on  a  United  States  public  stock market and which, if sold at the
prevailing market price at the time of each such release, would in the aggregate
result  in  $20,000,000  in  gross  proceeds from the sale of such securities to
Licensor.
     "LOCKUP  AGREEMENT"  means the Lockup Agreement entered into by Licensor in
accordance  with  paragraph  4.3  hereof.
"PATENTS"  means  those  patent  rights  set  forth  on  Schedule  A  hereto.
     "PRODUCTS"  means  products incorporating biological solution of human stem
cells  produced  or  otherwise  produced  or  manufactured  by  Licensor.
"RELATIONSHIPS"  means those business relationships between Licensor and certain
companies.
     "TERRITORY"  means  any  and  all countries in the World except for (i) The
Ukraine, (ii) the Dominican Republic, and (iii) up to three additional countries
which  (a)  are  designated  by  Licensor  in  writing  to Licensee, (b) are not
countries  in  which  Licensee  has already commenced Doing Business (as defined
herein),  (c) do not include the United States of America, and (d) are countries
in which Licensor commences Doing Business within 12 months of such designation.
1.     GRANT  OF  EXCLUSIVE  RIGHT
1.1  Licensor  hereby  grants  to Licensee an exclusive right and license in the
Territory  to  utilize  the  Patents,  Process and Products as permitted by this
Agreement  subject to the terms and conditions hereof, in any manner whatsoever,
in  connection with the operation of Licensee's Business involving the operation
of  clinics  for  treatment  with stem cell materials and technology, as well as
limited  sales  of  stem  cell  materials  to  universities, for research and to
private  labs  with appropriate supervision by licensee or licensor (hereinafter
referred  to  as  "License  Rights").  If Licensee wishes to transfer or further
sublicense  the "Patents " to any other person or entity , Licensee shall notify
Licensor  of  its such intention and shall provide Licensor with full details of
such  proposed  transfer  or proposed sublicense, including, but not limited to,
the name and address of the proposed transferee or sublicensee, the names of the
principals of such proposed transferee or sublicensee, the proposed scope of the
proposed  transfer  or sublicense, the qualifications of the proposed transferee
or sublicensee to engage in the business of utilizing the license, the financial
qualifications  and  responsibility  of  the  proposed  transferee  or  proposed
sublicensee  and  all  of  the terms and conditions of such proposed transfer or
proposed  sublicense.  Licensor shall have the right to approve or disapprove of
any  such  proposed  transfer

<PAGE>

or  proposed  sublicense  in its discretion, provided such refusal is reasonable
and  not unreasonably delayed, as well as the right to treat such proposal as an
offer  of  a  right  of  first  refusal  to  retake  Licensor's right under this
Agreement  to the extent of such proposed transfer or proposed sublicense on the
same  terms and conditions. In the event that Licensor approves of such proposed
transfer  or  sublicense,  Licensor  shall  be entitled to receive, and Licensee
shall  pay  to  Licensor  a  royalty  of  fifty  (50%)  percent  of  the  gross
consideration  (after  deduction  of  any  and  all reasonable costs or expenses
associated  with  entering  into  any  such  sublicense  agreement  which  are
appropriately  disclosed  to  and  documented  in full for Licensor) received by
Licensee  from  such  person or entity within thirty (30) days of any payment to
Licensee. Any and all agreements with any such sublicensee shall provide that in
the  event  any  such  sublicensee  does not pay any such obligation within such
thirty  day  period,  both  Licensor  and  Licensee  shall  have  the ability to
terminate  such  sublicense,  unless  Licensee  pays  any  and  all  amounts due
hereunder  from such sublicense to Licensor, in which case Licensor's ability to
terminate  such  sublicense  for  non-payment  shall be suspended for any period
during  which  Licensee  pays  such  amounts.
     1.2     Any  agreement to transfer or sublicense shall include all default,
termination  and  confidentiality  provisions  contained  in  this  Agreement.
 1.3  Licensee acknowledges that the Patents are the sole and exclusive property
of  Licensor,  subject only to the license hereby granted. Licensor acknowledges
agrees  and  understands  that  the  Patents  may  not  be  the  only  patents,
intellectual  property,  know  how  or other products utilized in the Licensee's
Business.  With  respect  to  any "improvements": (a) If during the term of this
Agreement,  Licensor  makes  any  improvements  to  the Patents, Licensor hereby
grants  Licensee  a  right  of first refusal to license said improvements on the
same  or  better terms and conditions offered to Licensor by any bona fide third
party  offeror;  (b)  If,  during the term of this Agreement, Licensor makes any
improvements,  modifications,  or  alterations  in  or  to  the  Patents
("Improvement"),  then  Licensor  shall notify Licensee of such Improvements and
provide  Licensee  with  sufficient  information  to permit Licensee to properly
analyze  the  impact  of  the  Improvement on the business of Licensee. Licensee
shall  have  thirty  (30) days within which to notify Licensor of its desire and
intention to license such Improvement, subsequent to which Licensee and Licensor
agree  to negotiate in good faith to determine the costs of such development and
enter  into  an  appropriate  license  agreement reflecting all economic factors
including  the  costs  of  such  Improvement  and  entering into an "Improvement
License  Agreement."  (c) If Licensee wishes Licensor to research and develop an
improvement  to any designated Patent or Patents and describe the nature of such
improvement  to  Licensor,  then  Licensor  shall  quote  Licensee  a  price for
researching  and  developing  such

<PAGE>

improvement  or  improvements,  the  parties  shall  enter  into an "Improvement
Development  Agreement"  with  respect  thereto  and,  upon  development of such
improvement, provided Licensee has discharged its obligations under the terms of
the  "Improvement  Development  Agreement",  Licensee shall be granted a license
with  respect  to  such  improvement on the terms of the Improvement Development
Agreement;  (d) If Licensee researches and develops an Improvement of any Patent
or  Patents  on  its  own,  and  at  its  own  sole  cost  and expense, it shall
immediately  notify  Licensor  thereof  and  cooperate  fully  with  Licensor in
patenting  such  improvement in Licensor's name, and Licensee shall be granted a
license  with  respect  to  such  improvement  at  no  additional  charge.
1.4  Licensor shall provide reasonable telephonic and electronic mail ("e-mail")
support  to  Licensee  on an as needed basis, during Licensor's regular business
hours.
 1.5 Licensee may build clinics or other appropriate facilities in the Territory
for  the operation of the proposed stem cell business as set forth herein at its
own cost and expense and choose any geographic site locations for the purpose of
administering, treating, selling (as limited herein), analyzing, and testing the
products  for  its  own  quality  control  purposes.  Subject to availability of
personnel  and  scheduling  to  be  mutually  agreed,  Licensor  shall provide a
commercially reasonable amount of training for technicians at such facilities to
Licensee payable by Licensee at Licensor's cost plus a reasonable markup. During
the  Initial Term and the Second Term, Licensor agrees to fully support Licensee
in these activities. Licensor agrees that with respect to each reimbursable cost
item  it will first obtain written approval from Licensee before expending funds
for  any  cost  item or items whose aggregate cost would exceed $1,000.00 in any
thirty  day  period.
 1.6  Upon  a  Liquidity $20,000,000 Event, Licensee shall become the beneficial
owner  of  20% of the Patents as set forth in Schedule A, as well as any and all
other  Patents  licensed to Licensee by Licensor in accordance with the terms of
this  Agreement,  with  full  title  and all property rights thereto without any
further  required  action  by  Licensor or Licensee. Licensor agrees to take all
further  actions  and  execute  any  and  all  additional documents necessary to
document  and  perfect  Licensee's  percentage  ownership  of  the  Patents.
Furthermore,  if  Licensor  desires to offer any portion of the existing Patents
for sale, Licensee shall have the right of first refusal for such Patents on the
same  or  better  terms as offered by any bona fide third party for such Patents
Licensor shall provide written notice to Licensee of any such bona fide offer to
purchase  and  Licensee shall have 30 days to elect to match such offer from the
date  of  receipt  of  the  notice.

<PAGE>

2.     DUTIES OF LICENSEE
2.1  Licensor  agrees  to  sell  and  provide and Licensee agrees to exclusively
purchase  from  Licensor  all  biological  solution of stem cell Allo Transplant
materials  from  Licensor  for  a  period  of  three years. For purposes hereof,
"Portion"  shall be defined to mean that quantity of biological solution of stem
cell  Allo Transplant materials required to treat one patient for one condition.
Such  Allo  Transplant  materials  shall  be  at a cost to Licensee of $6500 per
"portion",  or  such  lower  amount  as  shall  hereafter be mutually determined
between  Licensor  and  Licensee  during  such  three year term. Such cost shall
remain  the  same  during this period whether or not any such "portion" reflects
the  existing patents or updated or improved stem cell technology from Licensor.
Licensor agrees that Licensee shall be the exclusive purchaser of such stem cell
Allo Transplant material during such period provided that Licensee purchases (or
refers  customers  to  ICT  for direct sale or treatment by ICT) a minimum of 60
"portions"  in  any  given  twelve  month  period. In the event that Licensor is
unable  to  provide  all of the Allo Transplant stem cell materials requested by
Licensee during each year of the three year period, and subsequent to such three
year period, Licensee shall have the right to purchase Allo Transplant materials
from  other  vendors, subject to Licensor's absolute right, but not the duty, to
perform  reasonable  and  timely quality control with respect to such biological
solution  of  stem  cell  materials,  and  Licensee  shall  cooperate fully with
Licensor. In the event that Licensee does not purchase the minimum quantities of
materials set forth herein, Licensor shall have the right to sell such materials
to other parties (but Licensee shall remain entitled to purchase portions at the
prices  set forth herein). Licensee agrees to provide Licensor within 30 days of
execution  of  this Agreement an international irrevocable letter of credit (the
"Letter  of  Credit")  in  Licensor's  favor  for  the  three  year term of this
requirement  in  the amount of One Hundred Twenty Thousand Dollars ($120,000.00)
from a reputable and chartered bank in the United States of America securing the
minimum purchase requirement set forth above. The Letter of Credit shall provide
that upon the failure by Licensee to purchase and failure to pay for the minimum
number  of  portions  hereinabove  set forth, Licensor shall be entitled to draw
upon  the Letter of Credit at the rate of $2,000 for every portion less than the
minimum  purchased  without  any  further  notice  to  or  action by Licensee by
providing  a  notarized  affidavit  from  Licensor  to the bank advising of such
failure and drawing upon the Letter of Credit. In the event the Letter of Credit
is  drawn  upon  during  the three year period, Licensee agrees to replenish the
Letter  of  Credit  to the extent of any such draws. Except with respect to this
paragraph  relating  to  purchase  of  Allo  Transplant materials from Licensor,
Licensee  is  not  otherwise  prohibited  from  using

<PAGE>

any  other  persons'  or  entities'  non-Allo  stem  cell  product(s).
 2.3  Licensee  shall at all times during the Term of this Agreement be entitled
to  maintain  and  defend  the  Patents  and  prosecute  claims  to prohibit any
interference  with  the  Patents  by third parties. If and in the event that the
Licensee  becomes  aware  of  any  interference  with  the Patents by any party,
Licensee  shall  immediately  notify  Licensor thereof in writing, providing all
information known to Licensee or reasonably obtained by Licensee with respect to
such  interference.  In  the event Licensee fails to notify Licensor of any such
material  interference  within  30  days  of  knowledge of such an interference,
Licensee's  License rights as otherwise set forth herein in the particular State
(if  in  the  United  States  of  America)  or  Country  (if elsewhere) shall be
terminable  upon  notice  by  Licensee.
 2.4  Licensee  shall  be  solely  responsible  for the organization, operation,
marketing  and  management  of  its  business,  and shall be responsible for the
development  of  its own ongoing method of business operation, including but not
limited  to  the following: selection and establishment of business sites; sales
techniques; marketing plan/system and advertising practices; employee selection,
hiring  and  training; personnel policies and practices; hours of operation; and
all  other  such  ongoing  concerns in the course of Licensee's routine business
operation  and management. Licensee agrees that it is not subject to any control
by  Licensor  and  is not relying upon Licensor for any assistance regarding the
aforementioned  items  in  this  paragraph,  except for technological support as
hereinabove  provided.
 2.5  Licensee  may  file  and/or  record  any  and  all  necessary  forms  or
documentation  relating  to  the  operation  of its business, including, but not
limited to, any state application for registration of fictitious name, but it is
specifically understood and agreed that Licensee shall under no circumstances be
permitted  to  file,  record  or  register  any  trademark,  tradename  or other
identifying  material  of  Licensor,  or  to  utilize  any  of  the foregoing in
connection  with  its  promotion of the business and operations of the Licensee,
without  the  prior  consent  of  the  Licensor,  in  writing,  the  granting or
withholding  of such consent shall be in the sole judgment and discretion of the
Licensor.
 2.6  The  Parties acknowledge and agree that no partnership or joint venture is
created  by  this  Agreement  and that Licensee may not, without prior approval,
hold itself out as an agent or representative of Licensor, and may not incur any
liability  or  create  any  obligation  whatsoever  for  Licensor.
 2.7  At  all  times  Licensee shall conduct its business in accordance with all
material  applicable  federal, state and local laws, regulations and ordinances.
Licensee  shall  not,  either  during  or  after  the Term of this Agreement, do
anything,  or  aid  or  assist  any  other  party  to  do  anything, which would
materially  infringe  on,  harm,  impair,  or

<PAGE>

contest  the  rights  granted  herein  to  Licensee with respect to the Licensee
Rights.
 2.8 This Agreement shall in no way whatsoever affect the business activities of
the  Licensor  presently in operation in The Ukraine, the Dominican Republic and
any  other  operations  of Licensor designated in the future as set forth in the
definition  of  "Territory"  and  shall not constitute any restriction upon such
activities.
 2.9  Within 30 days of the execution of this Agreement, Licensee agrees to take
all  action  necessary  to  provide  for  the  addition of seats on its board of
directors so that the number of directors shall be five (5) in total. During the
Term,  Licensor  shall  have  the  right, but not the obligation, to appoint one
person  of  its  choice  to  Licensee's  board  of  directors.
3.     TERM
 3.1  Unless  terminated  in  accordance  with the terms of this Agreement, this
Agreement  shall  be effective as of the date of execution of this Agreement and
shall  remain  in  effect  for  the  remainder of the year 2005 and the Ten (10)
calendar  year period thereafter ("Initial Term"). Provided that Licensee is not
in  default  in  the  payment  of  a  material  money  obligation to Licensor in
accordance  with  the  terms of this Agreement, and provided that this Agreement
has  not  previously  been  terminated  in  accordance  with  the  provisions of
Paragraph  8.1  hereof  during  the Initial Term hereof, Licensee shall have the
right  to  renew  such License and Agreement for an additional Ten (10) calendar
year period following the Initial Term by giving Licensor notice, in writing, of
its  election to renew this Agreement, which such notice shall be given not more
than  180 days nor less than 60 days prior to the expiration of the Initial Term
of  this Agreement. In the event Licensor determines that Licensee may not renew
this  Agreement  because  of  a  default  in  the  payment  of  a material money
obligation  to  Licensor,  it  shall immediately provide Licensee with notice of
such default and shall provide Licensee the right to cure such default within 60
days,  upon  satisfaction of which the election to renew this Agreement shall be
immediately  effective.
4.     PRICE  AND  PAYMENT
 4.1  License  Consideration. Licensee shall tender Licensor a total license fee
      -----------------------
(the  "License  Fee") consisting of Licensee's common stock (the "Common Stock")
in  an  amount  equal to twenty percent (20%) of the Licensee's total issued and
outstanding common stock at the date of this Agreement on a fully diluted basis.
The  Common  Stock  shall  constitute  "restricted  securities"  as such term is
defined  in  Securities  and  Exchange  Commission  Rule  144  and  shall bear a
restrictive  transfer  legend on each certificate issued in connection with this
Agreement,  and  shall  not  be  subject  to  any

<PAGE>

securities  registration  rights  except  as  stated in this paragraph. Licensee
shall at its sole cost and expense include such shares in the first registration
statement  pertaining  to  Licensee's  securities filed by the Licensee with the
United  States  Securities  and  Exchange  Commission. The Common Stock shall be
issued  to  Licensor by Licensee within thirty (30) days following the effective
date  of  this  Agreement.
 4.2  Anti-Dilution. Pursuant to this paragraph, Licensor shall be provided with
      --------------
anti-dilution  rights  in  order  to  maintain its percentage equity interest in
Licensee  (taking  into  account  the  equity  at  the time of such event of the
officers  and  directors  of Licensee at the time of execution of this Agreement
and taking into consideration any sales or other dispositions of common stock by
Licensor),  in  the  event the current officers and/or directors of the Licensee
are  issued  additional shares of common stock of Licensee without delivering to
Licensee  consideration  for  such shares (as reflected on the audited financial
statements  of Licensee). However, these anti-dilution rights shall not apply to
any  private  placement or public capital raising activities of the Licensee and
other recapitalizations where current officers and directors of the Licensee may
purchase or otherwise acquire common stock of Licensee on the same terms offered
to other investors. Under such circumstances, Licensor shall be offered the same
opportunity to purchase or acquire Licensee's common stock at the same price and
terms as the proposed purchasers in such financing in order to maintain its then
percentage  equity  position  as  it relates to the position of the officers and
directors  at the time of this Agreement (taking into consideration any sales or
other  dispositions  of common stock by Licensor), but shall not be obligated to
make  such  purchase.  The  anti-dilution  rights  shall  terminate when (i) the
Licensee  lists  its  common stock on any national securities exchange above the
over-the-counter  bulletin board ("OTCBB"); or (ii) upon a Liquidity $20,000,000
Event.
 4.3  Licensor  and  Licensee  shall  enter into an appropriate lockup agreement
pursuant  to  which  Licensor  agrees (upon either effective registration of the
Shares  or  upon  the  availability  of  an  exemption  from registration of the
Shares),  Licensor and/or its designees or transferees will be permitted to sell
on  public security markets during any 30 day period no more than the greater of
(i)  5%  of  the  prior  months total trading volume (shares sold times price of
shares  sold)  or  (ii)  20,000  shares.
 4.4  Unless  the Shares have been otherwise registered for resale in accordance
with  paragraph  4.1  hereof,  and in the event that Licensor tenders any of the
Shares for removal of the legends required under Rule 144 on the Shares together
with  (i) an affidavit that Licensor has met all of the requirements of Rule 144
and  (ii)  an  opinion  of  legal  counsel that such requirements have been met,
Licensee  shall  immediately instruct its transfer agent to remove the legend on
such  tendered  Shares  in  accordance  with Rule 144. Provided however, that if
Licensee  provides  an  opinion  of

<PAGE>

independent  legal  counsel  that  such removal is not permissible in accordance
with such Rule 144, Licensee shall have no such obligation to remove the legend.
In  the  event  that  Licensee  fails to cause the removal of such legend as set
forth  herein,  without  limitation  to any other right of Licensor under law or
equity,  Licensor  shall  have  the  right  to  seek specific enforcement of the
requirements of this paragraph 4.4 as well as any and all costs (including legal
fees) associated with such enforcement, and shall have the right to seek damages
equivalent  to  any  and  all  lost profits caused by the failure of licensee to
remove  the  legend  on  the  tendered  shares  as  set  forth  herein.
 4.5 Licensor shall in its sole and absolute discretion have the power to adjust
and/or  modify  its  rights  under  this  Agreement  so  as  to achieve the most
favorable  and  advantageous  tax  consequences  resulting to Licensor from this
Agreement  and  provided,  that such modification shall not result in accrual of
any  material  negative  consequence  to  Licensee.
                      5. NON-COMPETITION & NON-SOLICITATION
 5.1 During the term of this Agreement, each of Licensor and Licensee shall not,
without  the  prior written consent from the other party, directly or indirectly
(including  without  limitation,  through  any  affiliate  of either party), (i)
solicit  or request any person who is at the time an employee of or a consultant
of  the  other  party  to  leave  the  employment  of or terminate such person's
relationship with that party or (ii) employ, hire, engage or be associated with,
or  endeavor  to  entice  away  from  the  applicable party any such person. Key
employees  of  the  Licensor  should be available to serve as Consultants to the
Licensee,  and  serve  on  the  Corporate  Advisory  Board  on  terms  which are
satisfactory  to  Licensor,  Licensee  and  the  employees  of  Licensor.
 5.2  During  the  term  of  this  Agreement,  Licensor  and Licensee shall not,
directly  or  indirectly (including without limitation, through any affiliate of
either  party)  (i)  solicit  any  existing  customer  of  the other party, (ii)
intentionally  attempt  to  limit  or  interfere  with  any  permitted  business
agreement  or  relationship  existing  involving  the  other  party  and/or  its
affiliates  with  any third party; or (iii) disparage the business reputation of
the  other  party  (or  its  management  team) or (iv) take any actions that are
harmful  to  the  other party's goodwill with its customers, providers, vendors,
employees,  the  media  or  the  public.
6.  CONFIDENTIALITY
     6.1     Neither Licensor or Licensee shall use or divulge or communicate to
        any person (other than those whose province it is to know the same or as
                                                                    permitted or

<PAGE>

contemplated by this Agreement or with the written approval of the other party
or as may be required by law):
(i)     any Confidential Information; or
(ii)     any  of  the  terms  of  this  Agreement
 6.2  Licensor  and  Licensee  shall  prevent  the  unauthorized  publication or
disclosure  of  any such information, materials or documents and ensure that any
person  to  whom  the information, materials or documents are disclosed is aware
that  the  same  is  confidential  and  is covered by a similar duty to maintain
confidentiality.  Licensor  and  Licensee  shall each employ its best efforts to
ensure  that  its  directors,  shareholders,  employees,  consultants, agents or
advisors  are  aware  of  and comply with the confidentiality and non-disclosure
provisions  contained  in  this  Section.
7.     LEGAL  RELATIONSHIP
 7.1  Nothing  herein  shall  contain  any facts as to suggest that Licensor and
Licensee  are  engaging  in  a joint venture or partnership. Neither party shall
have  any  authority  to  bind the other to any legal obligation. Licensee shall
only  contract  with  Customers  on  its  own  behalf.
     7.2     In  the  event  that  Licensor  or Licensee are acquired by another
entity,  or  there  is  a  change of control within either Party, this Agreement
shall continue to exist, with all relative rights, privileges, titles, and shall
be assigned and transferred in its entirety to the new, successor or reorganized
entity.
8.     TERMINATION
 8.1  Licensor  shall  not  terminate  or  limit  Licensee's  rights, except for
Licensee's  material  non-performance, which "non-performance" shall include (i)
failure to deliver the common stock within the time frame set forth in paragraph
4.1  hereof or to remove restrictive legends as provided herein, (ii) failure by
Licensee  to  have  its common stock traded on a United States public securities
market  (including  without  limitation the Over-the-counter Bulletin Board, the
Pink Sheets, the Nasdaq Stock Market, or the American Stock Exchange) within six
months  of  the  date  of  this Agreement, (iii) Except in the case of a Liquity
$20,000,000  Event  (in  which  case  this  shall  not  be  a  termination), the
commencement  by  or against Licensee of any voluntary or involuntary proceeding
under  any  bankruptcy, reorganization, arrangement, insolvency, readjustment or
debt,  receivership,  dissolution,  or  liquidation  law  or  statute  or  any
jurisdiction,  whether  now  or  hereafter  in  effect;  or  the

<PAGE>

adjudication  of  Licensee  as  insolvent  or bankrupt by a decree of a court of
competent  jurisdiction. In the event of non-performance, notified in writing by
Licensor  at  any  time  during  the  term of this Agreement and its extensions,
Licensee shall be allowed a cure period of thirty (30) days in which to cure its
non-performance  and  to  implement  a  remedy  deemed  reasonably acceptable to
Licensor, which, if same is acceptable to Licensor, Licensor shall then promptly
and  diligently  prosecute  to  completion.  The  failure by Licensee to cure or
diligently  prosecute  a  remedy accepted by Licensor to completion as aforesaid
shall  result  in  termination  without  further  notice or opportunity to cure.
 8.2  This  Agreement  may be terminated by Licensee, upon sixty (60) days prior
written  notice to Licensor if Licensor breaches any of its material obligations
under  this  Agreement  and  such breach is not cured within such sixty (60) day
period.
     9. EFFECT OF TERMINATION On the termination of this Agreement:
 9.1  The  License grant and all rights and obligations of the parties hereunder
shall  automatically  terminate  except  for such rights of action as shall have
accrued  prior  to  such  termination  and  any obligation which expressly or by
implication  may  be intended to come into or continue in force on or after such
termination;
 9.2  Licensee  shall,  (i)  at its own expense, return to Licensor or otherwise
dispose of as Licensor may instruct, all technical and promotional materials and
other  documents  and  papers  whatsoever  sent  to Licensee and relating to the
Confidential  Information,  Products  or  the  business  of Licensor (other than
correspondence  between  the  parties,  copies  of  which  shall be delivered to
Licensor)  and  all  property  of Licensor in Licensee's possession or under its
control,  and  (ii)  immediately  cease  the use of the Patents and Confidential
Information
                 10. REPRESENTATIONS AND WARRANTIES OF LICENSOR
10.1  Licensor  currently  operates  a  stem  cell biological solution producing
clinical treatment business and research facility from and in Kiev, The Ukraine.
10.2  Licensor  warrants  and  represents  that  the  Patents have been formally
granted  by  the  government  of The Ukraine and former USSR. All of the Patents
which  are  ultimately  submitted  for  registration in the United States may be
contested  and  there is no guarantee that the Patents will not be challenged in
the  future.
   10.3 Licensor warrants and represents that Licensee is under no obligation to
        purchase, lease, take possession of, or receive any products, equipment,
                                                                       supplies,

<PAGE>

services or assistance with which to start its business, either from Licensor or
from  an  entity  recommended  by  Licensor,  other than minimum annual purchase
requirements  required  pursuant  to  paragraph  2.1  hereof.
10.4  Licensor shall not, during the Term of this Agreement, do anything, or aid
or  assist any other party to do anything which would infringe on, harm, impair,
or  contest the License Rights granted herein except in the event of a breach of
this  Agreement  by Licensee, except that Licensor shall have the right to carry
on  its  research  and  clinical  studies.
10.5  Licensor  warrants  and  represents  that the Patents, the Process and the
Products will provide the technology and information necessary to effectuate the
Licensee  Business  intended  in  this  Agreement.
10.6  Licensor  acknowledges  the  shares  of  common  stock to be issued by the
Licensee  and delivered to Licensor pursuant hereto will not be registered under
the  Securities  Act  of 1933, as amended, Chapter 517, Florida Statutes, or any
other states' securities laws. The shares are issued under applicable exemptions
from  the  securities registration requirements of such statutes. The exemptions
being claimed include, but are not necessarily limited to, those available under
Section  4(2)  of  the  Securities Act and Section 517.061(11) Florida Statutes;
and,  the  reliance  by  the  Licensee  upon  the exemptions from the securities
registration requirements of the federal and state securities laws is predicated
in  part  on the representations, understandings and covenants set forth in this
Agreement.
10.7  Licensor  acknowledges  and agrees that in connection with the issuance of
Licensee's common stock, Licensor will execute a stock subscription agreement in
the  form  annexed  hereto  as  Schedule  D.
11.     INTELLECTUAL  PROPERTY  RIGHTS
11.1  All  Intellectual  Property  Rights, including without limitation patents,
designs,  utility  models, copyrights, trade or service marks, trade secrets and
other  proprietary  information,  in or relating to the Patents and Products and
any  other  products  and  services,  without respect to whether it is under the
license  hereunder  or otherwise provided by or used by Licensee with Licensor's
permission, or related thereto and all improvements thereto are and shall remain
the  sole  and  exclusive  property of Licensor. Except as otherwise provided in
this  Agreement,  Licensee  shall  have  no  right  to use or obtain for its own
benefit  or  grant  any licenses with respect to the Patents or Products, or any
other  related  products  or  services or any of the Patents therein or relating
thereto.

<PAGE>

                                12. MISCELLANEOUS
 12.1  Licensee  and  Licensor  each  shall  conduct  its  business  in material
compliance  of  all  applicable  laws,  ordinances,  regulations  and  other
requirements  of  any  federal, state, county, municipal or other government and
will  obtain  all  necessary  permits, licenses or other consents for the lawful
operation  of  its  business, the failure of which would have a material adverse
impact  on  the  business  of  such  party.
12.2  Notices.  Any  notice, demand or delivery to be given or to be served upon
      --------
any  party  in  connection  with  this Agreement must be in writing, and must be
given  by  a recognized international courier (e.g., DHL or Federal Express) and
shall  be  deemed  to  have been received on the date such notice is placed with
such international courier or, if given otherwise than by international courier,
it  shall  be  deemed to have been received on the date that it is personally or
directly  delivered  to  the  party  to  whom  it is addressed. Such notices, as
provided  herein, shall be given to the parties hereto at the following address:
     Licensor:     INSTITUTE OF CELL THERAPY ("ICT") Yuri Orlikov, President
                   4A Sklyrenko Street
                   Kiev, Ukraine 04073

     Licensee:     STEM CELL THERAPY INTERNATIONAL CORP.
                   Calvin Cao, Chairman
                   2203 North Lois Ave., 9th Floor
                   Tampa, Florida 33607

     Any  party  hereto  may  at any time by giving ten (10) days' prior written
notice to the other party hereto, designate any other address in substitution of
the  foregoing  address  to  which  such  notice  shall  be  sent.
 12.3  Licensee  and  Licensor acknowledge that the parties have not intended to
create  a  franchise  relationship  between themselves and that Licensor has not
represented  this  licensing  arrangement  to  be a "franchise" as defined in 16
C.F.R.   436  et.  seq.,  or  as defined in any applicable state franchise laws,
prior  to  or  during the negotiation of this Agreement. The parties acknowledge
that  the  Licensor  has  made  no  representation  that  any  form  of business
operations  or  management  plan,  manual,  or  advice, or any marketing plan or
system,  would  be  provided to or necessarily implemented by Licensee. Licensee
acknowledges  that  Licensee  has  not been provided with, or required under the
terms  of  this  Agreement to adopt or utilize any marketing plan or system, nor
has  Licensor  prescribed  to  Licensee,  in  whole  or  in
<PAGE>

part,  any  form  of  marketing  plan  or  system in relation to this Agreement.
Licensee  further  acknowledges  that  Licensee  has not been required under the
terms  of  this  Agreement to adopt the business format of, or a business format
substantially  similar  to the business format utilized by Licensor. The parties
agree  that  in  the  event it is determined that a franchise agreement has been
entered  into by the parties, the Licensee acknowledges that it has received the
necessary  information  from  the  Licensor  as  required  by  the Federal Trade
Commission;  further  that  Licensor has made no representations relating to the
potential  income  from operations by Licensee and that a copy of this Agreement
was  furnished  to  the  Licensee  at least five (5) days prior to the execution
hereof.
 12.4  This  Agreement  contains  the  entire  agreement  of  the parties and no
representations, inducements, promises or agreements, oral or otherwise, between
the  parties  not embodied herein shall be of any force or effect. No failure of
Licensor  to exercise any power given it hereunder, or to insist upon the strict
compliance of Licensee of any obligation hereunder, and no custom or practice of
the  parties  at  variance  with  the  terms hereof shall constitute a waiver of
Licensor's  right  to  demand  exact  compliance  with  the  terms  hereof.
12.5 This Agreement shall be governed by and construed solely and exclusively in
accordance  with  the  laws  of  the  state  of  New  York without regard to any
statutory  or  common-law  provision  pertaining  to  conflicts  of  laws.
12.6  The  Parties agree that all controversies, claims, disputes and matters in
question  arising  out  of,  or  related  to, this Agreement, the breach of this
Agreement,  the purchase of the Licensee's securities pursuant to this Agreement
or  any other matter or claim whatsoever shall be decided by courts of competent
jurisdiction  in  New  York,  New  York, to the exclusion of all other places of
venue,  for  all  matters  that  arise  under  this  Agreement.
 12.7 If Licensor creates new Intellectual Property which is not an improvement,
modification  or  alternation  to  the  Technology reflected herein and which is
related  in  any way whatsoever to Stem Cell therapy or research, Licensee shall
have  a  right  of  first  offer  to  obtain  an  exclusive  license to such new
Intellectual  Property  provided, both parties can reach an acceptable agreement
concerning  the  price,  and  shall  have a right of first refusal to accept any
license with respect to such new Intellectual Property which is made to any bona
fide  third party on the same or better terms and conditions as proposed by such
third  party.
 12.8  In  the  event it becomes necessary for either party herein to seek legal
means  to  enforce the terms of this Agreement, the prevailing party is entitled
to  payment  of  all  of  its  reasonable  attorneys'  fees, costs and expenses,
including  any  cost reasonably and necessarily incurred by the prevailing party
as  a  necessary  incident  to
<PAGE>

not  be  an  adequate  remedy  for any breach or threatened breach of any of the
provisions  of  this Agreement and that, in such event, they may, in addition to
any  other  rights  and  remedies existing in their favor, apply to any court of
competent  jurisdiction  in  New  York,  New  York  for  specific  performance,
injunctive and/or other relief in aid of arbitration to preserve and protect the
rights  of  the  parties  pending  action  by  the  arbitration  panel.
12.10  This  Agreement  may  be  executed in several counterparts, each of which
shall  be  deemed  an original. A facsimile signature on this agreement shall be
deemed  to  be  an  original.
12.11  The  parties agree that each has participated equally in the creation and
drafting  of  this  Agreement, and that each party to this Agreement has had the
opportunity  to  seek  independent  legal  counsel  prior  to entering into this
Agreement.
     IN WITNESS WHEREOF, the parties have executed this Agreement on the date
set forth above.

"LICENSOR"

INSTITUTE OF CELL THERAPY

     By:____________________
        YURI ORLIKOV, President

"LICENSEE"

STEM CELL THERAPY INTERNATIONAL CORP.

     By:______________________
        Calvin Cao, Chairman

<PAGE>

                                   Schedule A
                        AUTHORS OF THE MONOGRAPH POSSESS
                              THE FOLLOWING PATENTS
                             AND METHODICAL GUIDES:
1.     Patent ~560613. The method of erythrocytes preservation     1977 1975
USSR
2.     Patent ~645633. The method of blood leukocytes preservation 1978 1977
USSR
3. Patent ~825081. The method of blood leukocytes preservation 1981     1979
                                                                            USSR
4. Patent ~1017251. The method of a human ovary tissue preservation     1981
1979USSR

5.     Patent ~1410954. The method of treatment of anemias in pregnant     1983
1981     USSR
6.     Patent ~1 3709. The method of treatment of anemias in pregnant     1997
1997Ukraine
7.     Patent ~1402781. The container for freezing of biological objects
1988
1985     USSR
8.     Patent ~8457. The container for freezing of biological objects 1997 1997
Ukraine
9.     Patent ~1 706502. The method of preservation of human embryonic liver
hemopoietic cells 1988 1986 USSR
10.     Patent ~13687 The method of preservation of human embryonic liver
hemopoietic cells 1991     1989     Ukraine
11. Patent ~1 734621. Cryoprotector of hemopoietic cells     1997     1989  USSR
12. Patent ~16859. Cryoprotector of hemopoietic cells     1995     1993  Ukraine

13.     Application 93080788. The method of human immunodeficiency virus
treatment (HIV) 1995 1993 Ukraine
14.     Application 93090874 The method of treatment of cytostatic disease
1997 1995 Ukraine
15.     Application 93251432. The method of treatment of pancreatic diabetes
1995     Ukraine
16.     Application 93121711. The method of treatment of aplastic anemias 1994
Ukraine
17.     Application 95125139. The method of prevention of an acute radiation
sickness in

<PAGE>

lethally radiated animals 1993     1993 Ukraine
18.     Patent ~22981. The method of treatment of cerebral motional defects in
patients
who have undergone craniocerebral injury     1997 1993
                                     Ukraine
19.     Patent ~ 46673  . The method of cryo-preservation of human hemopoietic
cells
1997 1995 Ukraine
20.     Patent ~ 2233589 The method of cryo-preservation of human hemopoietic
cells 2004 2002 Russia
21.     Patent ~ 46675 A. The way of a low-temperature cell bank operating 2003
2002     Ukraine
22.     Patent ~ 52502 A. The method of therapy of prostate gland cancer 2003
2002Ukraine
23.     Patent ~ 56085 A. The method of obtaining a preparation of suspension of
placenta cells 2003 2003 Ukraine
24.     Patent ~ 59096 A. The method of biological preparations obtaining from
placenta     (variants) 2003 2003 Ukraine
25.     Patent ~ 60238 A. The cryopreservative content of hemopoietic cells of
donors' cord blood and its components 2003 2003
                                     Ukraine
26.     Patent ~ 63844 A. Device for registration of processes in biological
tests
2003 2003 Ukraine
          SCIENTIFIC-PRACTICAL WORKINGS-OUT ARE RESERVED BY COPYRIGHTS:
1.                .-.,          ,           ,          -
     (                             ).  -        . -     :              , 2004. -
250  .
2.              ,            .-.,           ,                      . -    :
     -    , 2004. -136 .
3.     Certificate    ~  511   The  method  of  treatment  of  severe  vascular
pathology  of an organ of vision, inflammatory and dystrophic eyes diseases with
the  help  of transplantation of cryopreserved hemopoietic human embryonic liver
cells,  and  application of biologically active compounds of embryonic tissues .
4.     Certificate    ~  1238  G.S.  Lobyntseva.  Dissertation on obtaining of a
doctor's  degree in biology upon a theme:  Cryopreservation of hemopoietic cells
of  human  embryonic  liver  .
5.     Certificate    ~ 2073  Cryopreservation of testicles tissue of human
fetuses for clinical application .
6.     Certificate    ~ 4952  Guide to purveyance and cryopreservation of
hemopoietic

<PAGE>

human  cells  and  Instruction  on  usage  of  hemopoietic  cells  .
     The  medical staff is represented by workers who have scientific degrees of
doctors  and  candidates  of sciences, the State prize laureates, professors and
assistant  professors  in  all  areas  of  clinical  therapy.

<PAGE>

                                   SCHEDULE B
                                    TREATMENT
     Biological preparations can produce a positive effect on age-related and
posttraumatic pathologies:
Cardiovascular system diseases: myocardial infraction, cerebral atherosclerosis,
essential hypertension, ischemic heart disease, neurocirculatory dystonia.
Systemic diseases of connective tissue: atrophic arthritis, systemic angitis,
systemic lupus, systemic scleroderma, and rheumatism.
1.     Respiratory diseases: bronchial asthma, bronchitis, chronic pneumonias.
2.     Diseases of the digestive tract: gastric and duodenal ulcer, nonspecific
ulcerative colitis, cholecystites, pancreatites, and colitis.
3.     Liver diseases: cirrhosis, viral and toxic hepatitis, acute and chronic
renal-hepatic insufficiency.
4.     Kidney and urinary tract diseases: pyelonephritis, cystitis, urethritis,
urolithiasis.
5.     Endocrine diseases: diabetes of types I and II, hypothyroidism,
suprarenal insufficiency, diabetes complication, endocrine derangements.
6.     Obstetrics  and  gynecology: premature detachment of the normal placement
of  the  placenta, pre-term delivery, toxicosis of pregnancy, miscarriage, fetal
hypotrophy,  immunological  conflict,  endomethriosis,  sterility,  menopause,
climacteric  neuroses,  chronic  inflammatory  genital  diseases.
7.     Diseases  of  the  nervous  system:  migraine, cerebral spastic infantile
paralysis, neuralgias, polyneuropathies, radiculopathies, neuritis, consequences
     of  a  cranio-cerebral  trauma,  encephalitis  and  stroke.
8.     Oncological  diseases  of  the  central  nervous  system.
9.     Cerebral  atrophic  processes  of  different  genesis.
10.     Epilepsy  and  spastic  syndromes  of  children  and  adults.
11.     The  consequences  of  cerebral  strokes.
12.     Huntington's  chorea,  ataxias.
13.     Atherosclerosis,  multiple  sclerosis  with  spinal  cord  lesions.
14     Parkinson's,  Alzheimer's,  Down's,  Strumpell's  diseases.
15     Serious  traumas  of  the  spinal  cord  and  cerebrum.
16     Surgical diseases: osteomyelites, fractures (long term), reconstructive
operations on bone tissue for various traumas and surgical interventions.

<PAGE>

17.     Malignant neo-plasms.
18.     Immuno-deficiencies.
19.     AIDS.
20.     Infectious diseases.
21.     Allergic and auto-immune diseases.
22.     Blood diseases: anemia, leukopenia, thrombocytopenia, leukemia,
hemoblastosis.
23.     Skin diseases: psoriasis, eczema, trophic ulcers, decubituses,
neurodermatitis, consequences of endured venereal diseases.
24.     Ocular diseases.
25.     Ear, throat, and nose diseases.
26.     Dental and oral cavity diseases.
27.     Mental diseases and sexual disorders: depression, irritation,
aggression, apathy, sleep and memory disorders.
28.     Male and female sexual pathology: impotency, sterility, decrease of
potency and libido.
29.     Long-term chronic diseases of the internal organs.
30.     Gerontology.
31.     Rejuvenation: increase of vitality, slowing down of pre-senility, life
prolongation, memory improvement, and the improvement over quality of life.

<PAGE>

                                   SCHEDULE C
                         Form of Subscription Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]